FDA Approves First Vaccine for Chikungunya Virus, a Global Health Threat

The U.S. Food and Drug Administration (FDA) has approved Ixchiq, the first vaccine for chikungunya, a mosquito-borne virus that is considered an emerging global health threat. The vaccine, made by Valneva, is approved for individuals aged 18 and older who are at risk of exposure to the virus. Chikungunya is transmitted through mosquito bites and can cause severe disease and prolonged health problems. The vaccine's safety and efficacy were tested in clinical trials, with most participants showing protective antibody levels. Common side effects include headache, muscle pain, and tenderness at the injection site. The vaccine is seen as an important advancement in preventing this debilitating disease with limited treatment options.